Research programme: in situ microparticles - Rovi

Drug Profile

Research programme: in situ microparticles - Rovi

Alternative Names: Letrozol ISM®; Letrozole-ISM®; Paliperidone-ISM®

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rovi
  • Class Benzodiazepines; Isoxazoles; Nitriles; Oxazepines; Piperidines; Pyrimidinones; Small molecules; Thiazepines; Triazoles
  • Mechanism of Action Aromatase inhibitors; Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer
  • No development reported Schizophrenia

Most Recent Events

  • 28 Jul 2016 Rovi plans a phase I trial for Breast cancer (Hormone-dependent) in USA in second half of 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in Spain (IM, Injection)
  • 31 Dec 2007 Preclinical trials in Breast cancer in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top